Post-earnings recap
Reported
Mon, May 11, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kodiak Sciences reported a loss per share that was slightly worse than expected, but the stock rose by 2.56% following the earnings announcement. Investors may be reacting positively to management's comments about progress in clinical trials, indicating potential future growth. The lack of revenue data and guidance suggests uncertainty about immediate financial performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | -1.31% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a cautious optimism about their future projects. They are focused on maintaining momentum in their clinical development.
Management highlighted ongoing progress in their clinical trials.
They emphasized their commitment to advancing their pipeline despite current challenges.